ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ruxolitinib

Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.

Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.

Drug pageRuxolitinib: every studyAll 302 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 13, 202390 company-led studies, 14 open or runningNext primary completion: Dec 9, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyteits history only689 open or runningphase 4since Jan 13, 2023Jul 30, 2007Dec 9, 2026phase 1 · NCT07049575
Novartisits history only214 open or runningphase 4since Mar 16, 2012Jul 6, 2009May 10, 2029phase 4 · NCT06824103
Suzhou Junjing BioSciences11 open or runningphase 2since Mar 27, 2025Mar 27, 2025Oct 31, 2027phase 2 · NCT06909136

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Suzhou Junjing BioSciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2025First study: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyFirst studyNCT06909136 · 33 enrolled · China

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyNCT06909136

TargetBeta

“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

The one study Suzhou Junjing BioSciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06909136Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly · China2Active, not recruitingOct 31, 202733

How it is read

Names in the registry

  • “Ruxolitinib”, 44 entries
  • “Ruxolitinib cream”, 14 entries
  • “Ruxolitinib Cream”, 11 entries
  • “ruxolitinib”, 6 entries
  • “Ruxolitinib phosphate cream”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.